A new inborn error in bile acid synthesis, manifest in identical infant twins as severe intrahepatic cholestasis, is described involving the delta 4-3-oxosteroid 5 beta-reductase catalyzed conversion of the key intermediates, 7 alpha-hydroxy-4-cholesten-3-one and 7 alpha,12 alpha-dihydroxy-4-cholesten-3-one for chenodeoxycholic and cholic acid synthesis, to the respective 3 alpha-hydroxy-5 beta (H) products. This defect was detected by fast atom bombardment ionization-mass spectrometry from an elevated excretion and predominance of taurine conjugated unsaturated hydroxy-oxo-bile acids. Gas chromatography-mass spectrometry confirmed these to be 7 alpha-hydroxy-3-oxo-4-cholenoic and 7 alpha,12 alpha-dihydroxy-3-oxo-4-cholenoic acids (75-92% of total). Fasting serum bile acid concentrations were greater than 37 mumol/liter; chenodeoxycholic acid was the major bile acid, but significant amounts of allo(5 alpha-H)-bile acids (approximately 30%) were present. Biliary bile acid concentration was less than 2 mumol/liter and consisted of chenodeoxycholic, allo-chenodeoxycholic, and allo-cholic acids. These biochemical findings, which were identical in both infants, indicate a defect in bile acid synthesis involving the conversion of the delta 4-3-oxo-C27 intermediates into the corresponding 3 alpha-hydroxy-5 beta(H)-structures, a reaction that is catalyzed by a delta 4-3-oxosteroid-5 beta reductase enzyme. This defect resulted in markedly reduced primary bile acid synthesis and concomitant accumulation of delta 4-3-oxo-and allo-bile acids. These findings indicate a pathway in bile acid synthesis whereby side chain oxidation can occur despite incomplete alterations to the steroid nucleus, and lend support […] 
Introduction
Bile acids are important organic compounds in bile and are thought to be a major determinant and motive force for the generation of bile secretion at the canalicular level. The postnatal increase in bile secretion that occurs in the human and other species depends largely on the coordinate maturation of hepatic biosynthetic and transport mechanisms for bile acids. Pathways of bile acid synthesis from cholesterol in adults are relatively well defined (1) and involve various modifications of the steroid nucleus, including the conversion of the 3,3-hydroxy-A5 structure of this sterol to a 3a-hydroxy-5f3(H) structure, which is common to chenodeoxycholic and cholic acids, the principal bile acids in man. Hydroxylations at positions C-7 of the steroid nucleus, and C-12 for cholic acid, and oxidation of the side chain are also required. Studies of human fetal gallbladder bile indicate that while bile acid synthesis is relatively well developed in early gestation (2, 3) , alternative pathways in metabolism are operative during human development, including additional hydroxylations of the steroid nucleus (3) (4) (5) (6) (7) (8) (9) .
Inborn errors involving primary bile acid synthesis from cholesterol are considered uncommon, but studies of affected patients have led to a better understanding of the biochemical pathways. The most well documented inborn errors include cerebrotendinous xanthomatosis and the peroxisomal abnormalities (Zellweger syndrome, pseudo-Zellweger syndrome, infantile Refsums' disease, and neonatal adrenoleukodystrophy), all of which involve an impaired oxidation of the cholesterol side chain (10) . More recently a defect involving nuclear alteration of the 313-hydroxy-A5 structure of 7a-hydroxy-cholesterol was described in an infant with "familial giant cell hepatitis." This condition was characterized by excessive production of C24-bile acids having a 313-hydroxy-A5 structure (1 1, 12) .
In this report we describe a new inborn error in bile acid synthesis, namely a A4-3-oxosteroid 5j3-reductase deficiency, in identical twins with neonatal hepatitis which is reflected by an increased synthesis ofbile acids having a 3-oxo-A4-structure and allo(5a),bile acids.
Methods
Case histories. Monochorionic twin male infants S.G. and J.G. presented at birth with cholestatic jaundice. They were the product of a term uncomplicated pregnancy. The parents were not consanguineous. Jaundice, pale stools, and dark urine were noted on the first day of life. Initial liver tests revealed a total bilirubin of [5] [6] [7] mg/dl in both infants with a conjugated fraction of 5-6 mg/dl. Serum aminotransferase levels were normal or only slightly increased (serum glutamic oxaloacetic transaminase 103-133, U/liter, normal On electron microscopy bile canaliculi were small, sometimes slit-like in structure, and showed few or absent microvilli. There was a variable amount of electron dense material in the pericanalicular cytoplasm and within the canalicular lumen.
Analysis ofbile acids from urine, bile, and serum. Bile acids were extracted and concentrated from urine, bile, and serum samples by liquid-solid extraction using small cartridges ofoctadecylsilane bonded silica exactly as described in detail previously (14) .
A small portion ofthe urine and bile extracts (equivalent to 50 z1 of the original sample) was analyzed directly by fast atom bombardment ionization-mass spectrometry (FAB-MS)' (10, 15) . The remaining sample was analyzed by gas chromatography-mass spectrometry for total individual bile acids (16) . The methanolic extract was evaporated to dryness and bile acid conjugates solvolyzed in a mixture of tetrahydrofuran/l M trifluoracetic acid in dioxan/methanol (9:0.1:1 by vol) for 2 h at room temperature (17) . The volatile reagents were removed by evaporation in a stream of nitrogen gas and the sample was then subjected to enzymic hydrolysis using cholylglycine hydrolase (10 U) in phosphate buffer pH 5.8, overnight at 37°C. Bile acids were extracted from the hydrolysate by passage through a cartridge of octadecylsilane bonded silica. The methanolic extract was then passed through a small column of the lipophilic anion exchange gel, diethylaminohydroxypropyl Sephadex LH-20 (Lipidex DEAP) to remove neutral steroids and sterols. Unconjugated bile acids were recovered from the gel by elution with 5 ml 0.1 M acetic acid in 72% ethanol.
After addition of an internal standard (coprostanol 1-10 Mg) bile acids were converted to the methyl ester trimethylsilyl (Me-TMS) ether derivatives for analysis by gas chromatography and mass spectrometry (16, 18 .,P.'.! 14..
4--P-14-, (2) allo-cholic; (3) chenodeoxycholic; (4) trihydroxy bile acid possibly 3f,7a, 12a-trihydroxy-5a-cholanoic; (5) hyocholic; (6) 7a-hydroxy-3-oxo-4-cholenoic; (7) 7a, 12a-dihydroxy-3-oxo-4-cholenoic; internal standard-coprostanol. Bile acids identified in the chromatograms of healthy infant urine are denoted by letters and identifications listed in Table II Figure 3 . The electron impact (70 eV) ionization mass spectra of the Me-TMS ether derivatives of the two major components in the urine from twins with familial giant-cell hepatitis. These bile acids were identified as 7a-hydroxy-3-oxo-4-cholenoic acid (upper; peak 6 in Fig. 2 ) and 7a, 12a-dihydroxy-3-oxo-4-cholenoic acid (lower; peak 7 in Fig. 2 ). Ofthe minor peaks in the GC-MS profile, chenodeoxycholic acid and allo-chenodeoxycholic acid (3a,7a-dihydroxy-5a-cholanoic acid), allo-cholic acid (3a,7a, 12a-trihydroxy-5a-cholanoic acid) and 3a,6a,7a-trihydroxy-5(8-cholanoic (hyocholic acid) were identified from their mass spectra and GC retention indices. A number of minor compounds remain unidentified. Quantitatively, total urinary bile acid concentrations were elevated (Table I ) compared with a control group (Table II) of six healthy 4-mo old infants (0.63-2.25 gmol/ liter). The two A4-3-oxo bile acids accounted for up to 92% of the total bile acids excreted in the random samples of urine collected from both infants while being undetectable in the urine from healthy infants.
Biliary bile acid analysis The negative ion FAB-MS spectra (Fig. 1) of the gallbladder bile (50 1l) from one of these infants (S.G.) indicated the presence of relatively low concentrations of tauro-dihydroxy-cholanoic acids. In contrast to urine, there was no evidence for the presence of A4-3-oxo bile acids in bile, and there was also no detectable trihydroxycholanoates or glycine and sulfate-conjugated bile acids.
GC-MS analysis of the bile samples confirmed the FAB-MS data, indicating the presence of low concentrations of chenodeoxycholic acid (< 2.0 Atmol/liter), and traces of allo-chenodeoxycholic and allo-cholic acids (Table I) .
Serum bile acid analysis
Serum bile acids were not determined by the FAB-MS technique. Total individual serum bile acids were determined by GC and GC-MS after solvolysis/hydrolysis, purification, and derivatization. The GC profiles of serum from both infants were virtually identical and the chromatogram obtained from infant S.G. is shown in Fig. 4 . The major bile acid in serum was identified by mass spectrometry to be chenodeoxycholic acid. GC-MS analysis however, revealed the presence of allocholic acid, which co-eluted with chenodeoxycholic. The retention indices of the Me-TMS ether derivatives of these two bile acids are almost identical (32.14 MU for allo-cholic; 32.16 MU for chenodeoxycholic acid) and they were incompletely resolved under the GC conditions employed, but under the GC-MS scanning conditions a relatively pure mass spectrum could be obtained Fig. 5 (lower trace) . This mass spectrum shows all of the ions found in the Me-TMS ether derivative of cholic acid (although there is a trace of the chenodeoxycholic acid derivative present), but the relative intensities of the fragments produced under electron impact ionization conditions differ significantly from cholic acid. The origins of these ions have been discussed previously (21) and the spectrum is identical to previously published spectra of the Me-TMS ether derivative of allo-cholic acid (18, 21) . A large chromatographic peak with a shorter retention index than chenodeoxycholic acid was present in the serum from both infants. The mass spectrum of the Me-TMS ether derivative of this compound is shown in Fig. 5 (upper panel) . This 3,7-dihydroxy bile acid has a similar fragmentation pattern to that of chenodeoxycholic acid, however the relative intensities of the individual fragment ions are significantly different. The mass spectrum and GC retention index was found to be identical to the Me-TMS ether derivative of an authentic standard of allo-chenodeoxycholic ( 18) . A trihydroxy bile acid was also present in low concentrations in the serum (and in small amounts in urine) of both infants that had a retention index similar to the Me-TMS ether derivative of cholic acid, however the relative intensities of the major fragments in the mass spectrum differed. Although the authentic reference bile acid was unavailable, we tentatively suggest on the basis of retention values ( 18, 22 ) that this trihydroxy bile acid may be either 3f3,7a, 1 2a-trihydroxy-5a-cholanoic acid, or a mixture of this compound coeluting with small amounts of cholic acid. The serum of both infants also contained 7a-hydroxy-3-oxo-4-cholenoic and 7a, 12a-dihydroxy-3-oxo-4-cholenoic acids, and several other unidentified minor components.
The total bile acid concentrations determined from a single sample from each infant were 52.18 Amol/liter (S.G.) and 37.26 umol/liter (J.G.), respectively (Table I) ; significantly greater than for bile acid concentrations of similarly aged healthy infants (23) or healthy adults (24) . Because of the coelution of allo-cholic acid and chenodeoxycholic it was not possible to accurately determine the individual concentrations of these two bile acids, however from the relative ion-abundances it was estimated that chenodeoxycholate exceeded allo-cholic acid by approximately four-to fivefold. The A4-3-oxo bile acids accounted for up to 17% of the total serum, bile acids, while the allo-bile acids made up -30% of the total. fords the most appropriate and definitive screening procedure for the detection of inborn errors in the cholesterol-bile acid biosynthetic pathway (10, 25, 26) . Cholestasis can be confirmed by the finding of an elevated urinary bile acid excretion and a qualitative profile of the types of bile acid conjugates that are present may be obtained on samples of urine as small as 10-50 ,l in volume. Once a defect in bile acid synthesis is suspected, confirmation may be obtained by GC-MS analysis and characterization of increased excretion of intermediates (and/or their metabolites) in the pathway. Using the above approach, a defect in bile acid synthesis, involving a deficiency of the 3fl-hydroxysteroid dehydrogenase/isomerase enzyme was recently identified for the first time in an infant with a familial giant cell hepatitis (1 1, 12) .
The negative ion FAB-MS spectra of the urine samples (Fig. 1) of the twins reported here were unique, and not typical of FAB-MS spectra for previously described inborn errors in bile acid synthesis [e.g., see reference 10]. The FAB-MS spectra revealed two major bile acid structures that were exclusively taurine conjugated and had molecular ions consistent with unsaturated oxo-hydroxy-and unsaturated oxo-dihydroxy-C24 bile acids. These two compounds were definitively identified by GC-MS as 7a-hydroxy-3-oxo-4-cholenoic and 7a, 12a-dihydroxy-3-oxo-4-cholenoic acids and quantitatively accounted for between 75 and 92% of the total bile acids in urine and 12 and 17% of the total serum bile acids (Table I) . This markedly contrasts urinary (Fig. 1) , and serum bile acid composition of healthy infants of a similar age where A4-3-oxo bile acids were not detected by these techniques.
Biliary bile acid concentrations measured in one of the infants was extremely low (1.67 Atmol/liter) and bile contained mainly chenodeoxycholic acid and allo-chenodeoxycholic acid. There was no biliary excretion of these A4-3-oxo bile acids. Approximate estimates of daily bile acid synthesis can be made on the assumption that in these patients urinary excretion represented the sole route of bile acid loss. Daily urine volumes for the two patients were estimated from daily fluid intake to be 320 ml (J.G.) and 375 ml (S.G.), respectively; therefore total bile acid synthesis approximates to 4.6 umol/d (1.8 mg/d, J.G.) and 9.3 ,umol/d (3.7 mg/d, S.G.), which is markedly reduced compared to published figures for cholate synthesis rates in healthy infants (18-27 mg/d [27] ).
These results point to a defect in bile acid synthesis affecting the conversion of the A4-3-oxo intermediates into the 3a-hydroxy-5,B(H) products. In the classical pathways for cholic and chenodeoxycholic acid synthesis (Fig. 6) , cholesterol is first 7a-hydroxylated to give rise to 7a-hydroxy-cholesterol (28) , and this step is rate limiting (29) . 7a-Hydroxycholesterol is oxidized to 7a-hydroxy-4-cholesten-3-one by the action of 3,3-hydroxysteroid dehydrogenase/isomerase enzyme (30) . For cholic acid synthesis, 7a-hydroxy-4-cholesten-3-one requires 12a-hydroxylation, and 7a, 12a-dihydroxy-4-cholesten-3-one is formed (31) . These two A4-3-oxo intermediates are normally converted to cholestane-3a,7a-diol and cholestane3a,7a, 1 2a-triol, respectively, in two steps; (a) by reduction of the A4 bond, a reaction which is catalyzed by a NADPH dependent A4-3-oxosteroid 5f3-reductase enzyme (32, 33) to give rise to the 7a-hydroxy-5#-cholestan-3-one and 7a, 12a-dihydroxy-5f3-cholestan-3-one; and (b) by reduction of the 3-oxo group to a 3a-hydroxy group under the action of a 3a-hydroxysteroid dehydrogenase enzyme (32, 33) .
Following these changes to the steroid nucleus, side chain hydroxylation and oxidation occur to reduce the C27-sterol to a C24-bile acid (1). In the major pathway for bile acid synthesis in the adult it is generally accepted that side chain oxidation occurs only after the necessary modifications to the steroid nucleus have taken place.
Increased production of A4-3-oxo bile acids may be explained on the basis of a deficiency in the A4-3-oxosteroid 5fl-reductase enzyme (Fig. 6) . Under circumstances of inadequate primary bile acid formation or secretion as occurs in other inborn errors in the cholesterol-bile acid pathway (10) , a relative increase in the production of intermediates (or metabolites of these intermediates) takes place. In these infants, the increased levels of 7a-hydroxy-4-cholesten-3-one and 7a, 1 2a- 2154 Setchell, Suchy, Welsh, Zimmer-Nechemias, Heubi, and Balistreri quently converted by side chain oxidation to the respective AM-3-oxo-cholenoic acids. The finding of significant levels of these M4-3-oxo bile acids therefore provides evidence for a pathway in early life in which side chain oxidation takes place despite incomplete modifications to the C27-steroid nucleus. The presence of relatively high proportions of allo(5a-H)-bile acids further supports a deficiency or inactivity in hepatic M4-3-oxosteroid 5f3-reductase activity in these infants. Normally all-bile acids are minor constituents in mammals, although in some lower vertebrates they are major bile acids (34) . Several different pathways have been proposed for the formation of allo-bile acids in mammals (1) . One of these includes the action of intestinal micro-organisms. This pathway is unlikely in these infants because there is negligible biliary secretion of bile acids into the gastrointestinal tract and because of the relative immaturity in bacterial colonization of the gut at this age of life (35) . Formation of allo-bile acids has xylation and on cholic acid droxylase; (4) zA4-3-oxosteroid-5gi-reductase; (5) 3a-hydroxysteroid dehydrogenase. The defect in A4-3-oxosteroid 5f3-reductase activity led to an increased production of A4-3-oxosteroids with subsequent metabolism of these precursors by side chain oxidation to A4-3-oxo bile acids and all-bile acids (shown in boxes).
been demonstrated by a series of reactions using 5a-cholestanol as the precursor (36, 37) , but in these patients cholestanol levels were not determined. It has been shown that this sterol may be formed from 7a-hydroxycholesterol and 7a-hydroxy-4-cholesten-3-one by a novel pathway involving hepatic 7a-dehydroxylation in patients with cerebrotendinous xanthomatosis (38) . In these infants however, allo-chenodeoxycholic and allo-cholic acid are most probably formed from 7a-hydroxy-4-cholesten-3-one and 7a, 1 2a-dihydroxy-4-cholesten-3-one, the normal substrates for the A4-3-oxosteroid 5,B-reductase. Bjorkhem and Einarsson have demonstrated that in rats these two precursors, in the presence of NADPH, can be converted to the corresponding 3-oxo-5a analogues by liver microsomes (39) , and these can then be efficiently converted to 3a-hydroxy-5a-steroids in the cytosol. In rats, the capacity of the microsomal M4-3-oxosteroid 5a-reductase is high, but the quantitative importance of this pathway in man is unclear. It is probable that in the absence of an active A4-3-M4-3-Oxosteroid-50-Reductase: A Defect in Bile Acid Synthesis 2155 oxosteroid 5,3-reductase as appears the case in these infants, the A4-3-oxosteroid 5a-reductase becomes quantitatively important in the metabolic handling of the increased amounts of C27, A4-3-one intermediates formed, thereby leading to significant levels of allo-bile acids.
The presence of high concentrations of chenodeoxycholic in plasma, requires explanation. Chenodeoxycholic acid is the major bile acid formed in the fetus during early gestation (2, 3) , but at term in the healthy neonate, cholic acid concentrations exceed those of chenodeoxycholic acid (40) . This may be due to an immaturity in the separate pathway for cholic acid synthesis involving a microsomal 1 2a-hydroxylase and/or because of a suppression of the activity of this enzyme by other bile acids that accumulate in this condition. An alternative possibility is that chenodeoxycholic is formed via the pathway, proposed by Yamasaki et al. (41) , which involves initial formation of 26-hydroxycholesterol (42-44) . If this were the case, significant amounts of lithocholate and 3f-hydroxy-5-cholenoate might be anticipated, but this was not observed in these infants. In the early studies on the isolation and partial purification ofthe A4-3-oxosteroid 5fl-reductase from rat liver it was suggested that the reduction of the double bond in 7a, 1 2a-dihydroxy-cholest-4-en-3-one and 7a-hydroxy-cholest-4-en-3-one may be catalyzed by separate enzymes (32) . Furthermore, the activity of this enzyme preparation towards C19 and C21 steroids indicates either its heterogeneity or broad specificity. If there are several A4-3-oxosteroid 5f3-reductases in man then this could explain the preferential formation of chenodeoxycholic acid in these infants.
The FAB-MS analysis indicated that the principal mode of hepatic conjugation of bile acids was with taurine, which is also a characteristic feature of bile acid synthesis in the human fetus (3). There were small quantities ofglycine conjugates but negligible amounts of bile acids sulphates in urine and bile. The lack of significant sulphation of bile acids is consistent with observations for urinary bile acid excretion in healthy infants (8) , but contrary to the general findings in cholestatic liver disease where increase proportions of bile acid sulphates are found in serum (45) and urine (46, 47) . In these patients, this observation is not surprising, since 75-92% of the total urinary bile acids possess a A4-3-oxo structure thus making them unsuitable substrates for sulphate conjugation.
The mechanism by which these infants developed cholestasis is a matter of conjecture. Primary bile acids are essential to the development of bile flow. Both infants, however, were unable to synthesize adequate amounts of chenodeoxycholic acid, and cholic acid. Perhaps the increased production and/or accumulation of unsaturated M4-3-oxo bile acids led to the cholestasis. Unsaturated bile acids with a 3f-hydroxy-A5 configuration have been shown to be hepatoxic in animal models (48) , but to our knowledge bile acids with a A-3-oxo structure have not been examined. The solubility of these oxo bile acids is likely to be less than the respective hydroxy analogues with the potential for precipitation and accumulation within the hepatocyte.
Early diagnosis of inborn errors of this type may be important in the clinical management of these patients. Irrespective of the exact pathogenesis of the cholestasis we suggest that oral bile acid therapy be carefully evaluated as a stimulus for bile flow and improved elimination of toxic substances, including bilirubin. Bile acid therapy may also serve to inhibit cholesterol 7a-hydroxylation, the rate-limiting step in endogenous bile acid synthesis thereby preventing the accumulation of potentially toxic A4-3-oxo bile acid intermediates in a similar manner to the response seen in cerebrotendinous xanthomatosis (49, 50) .
In conclusion, we describe here a new inborn error in bile acid synthesis detected in twins presenting with familial giantcell hepatitis. It is of particular relevance that an inborn error involving a different, but early step in the synthesis of bile acids from cholesterol was recently reported in an infant with familial giant cell hepatitis (15) (16) (17) and unsaturated oxo bile acids have been reported to occur in infants with fatal liver disease (5 1).
